Skip to main content

Advertisement

SpringerLink
Log in

Immune regulation of procalcitonin: a biomarker and mediator of infection

  • Review
  • Published:
Inflammation Research Aims and scope Submit manuscript

Abstract

Procalcitonin (PCT) has recently emerged as a powerful biomarker for an early and accurate diagnosis of bacterial infection. Here we summarize our current understanding of the expression pathways of PCT, its potential cellular sources including immune cells, and factors inducing its secretion. Also addressed is the significance of increased blood PCT concentration, which may allow this molecule not only to act as a clinical biomarker but also as an active participant in the development and progression of infectious processes. Experimental approaches to delineate a better understanding of PCT functions, molecular pathways that modulate its expression and therapeutic opportunities to curtail its biological actions are discussed, as well.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341(8844):515–8.

    Article  PubMed  CAS  Google Scholar 

  2. Fioretto JR, Martin JG, Kurokawa CS, Carpi MF, Bonatto RC, de Moraes MA, Ricchetti SM. Comparison between procalcitonin and C-reactive protein for early diagnosis of children with sepsis or septic shock. Inflamm Res. 2010;59(8):581–6.

    Article  PubMed  CAS  Google Scholar 

  3. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39(2):206–17.

    Article  PubMed  CAS  Google Scholar 

  4. Gendrel D, Bohuon C. Procalcitonin in pediatrics for differentiation of bacterial and viral infections. Intensive Care Med. 2000;26(Suppl 2):S178–81.

    PubMed  Google Scholar 

  5. Meynaar IA, Droog W, Batstra M, Vreede R, Herbrink P. In critically ill patients, serum procalcitonin is more useful in differentiating between sepsis and SIRS than CRP, Il-6, or LBP. Crit Care Res Pract. 2011;2011:594645.

    PubMed  Google Scholar 

  6. Lai CC, Tan CK, Chen SY, Wang CY, Liu WL, Hou CC, Hsueh PR. Diagnostic performance of procalcitonin for bacteremia in patients with bacterial infection at the emergency department. J Infect. 2010;61(6):512–5.

    Article  PubMed  Google Scholar 

  7. Galetto-Lacour A, Zamora SA, Gervaix A. Bedside procalcitonin and C-reactive protein tests in children with fever without localizing signs of infection seen in a referral center. Pediatrics. 2003;112(5):1054–60.

    Article  PubMed  Google Scholar 

  8. Kim MH, Lim G, Kang SY, Lee WI, Suh JT, Lee HJ. Utility of procalcitonin as an early diagnostic marker of bacteremia in patients with acute fever. Yonsei Med J. 2011;52(2):276–81.

    Article  PubMed  Google Scholar 

  9. Wunder C, Eichelbrönner O, Roewer N. Are IL-6, IL-10 and PCT plasma concentrations reliable for outcome prediction in severe sepsis? A comparison with APACHE III and SAPS II. Inflamm Res. 2004;53(4):158–63.

    Article  PubMed  CAS  Google Scholar 

  10. Nylén ES, Snider RH Jr, Thompson KA, Rohatgi P, Becker KL. Pneumonitis-associated hyperprocalcitoninemia. Am J Med Sci. 1996;312(1):12–8.

    Article  PubMed  Google Scholar 

  11. Georgopoulou AP, Savva A, Giamarellos-Bourboulis EJ, Georgitsi M, Raftogiannis M, Antonakos N. Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis. J Crit Care. 2011;26(3):331.e1–7.

    Article  Google Scholar 

  12. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059–66.

    Article  PubMed  CAS  Google Scholar 

  13. Becker KL, Snider R, Nylén ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol. 2010;159(2):253–64.

    Article  PubMed  CAS  Google Scholar 

  14. Russwurm S, Wiederhold M, Oberhoffer M, Stonans I, Zipfel PF, Reinhart K. Molecular aspects and natural source of procalcitonin. Clin Chem Lab Med. 1999;37(8):789–97.

    Article  PubMed  CAS  Google Scholar 

  15. Zaidi M, Moonga BS, Bevis PJ, Bascal ZA, Breimer LH. The calcitonin gene peptides: biology and clinical relevance. Crit Rev Clin Lab Sci. 1990;28(2):109–74.

    Article  PubMed  CAS  Google Scholar 

  16. Peleg S, Abruzzese RV, Cote GJ, Gagel RF. Transcription of the human calcitonin gene is mediated by a C cell-specific enhancer containing E-box-like elements. Mol Endocrinol. 1990;4(11):1750–7.

    Article  PubMed  CAS  Google Scholar 

  17. Peleg S. Modified binding of proteins from calcitonin-negative tumor cells to the neuroendocrine-specific CANNTG motif of the calcitonin gene. Nucleic Acids Res. 1993;21(23):5360–5.

    Article  PubMed  CAS  Google Scholar 

  18. Monla YT, Peleg S, Gagel RF, Monia YT. Cell type-specific regulation of transcription by cyclic adenosine 3′,5′-monophosphate-responsive elements within the calcitonin promoter. Mol Endocrinol. 1995;9(7):784–93.

    Article  PubMed  CAS  Google Scholar 

  19. Snider RH Jr, Nylen ES, Becker KL. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Investig Med. 1997;45(9):552–60.

    PubMed  Google Scholar 

  20. Bolko P, Manuszewska-Jopek E, Michałek K, Waśko R, Jaskuła M, Sowiński J. Efficacy of procalcitonin measurement in patients after total thyroidectomy due to medullary thyroid carcinoma. Arch Immunol Ther Exp (Warsz). 2003;51(6):415–9.

    CAS  Google Scholar 

  21. Nishikura T. Procalcitonin (PCT) production in a thyroidectomized patient. Intensive Care Med. 1999;25(9):1031.

    Article  PubMed  CAS  Google Scholar 

  22. Morgenthaler NG, Struck J, Chancerelle Y, Weglöhner W, Agay D, Bohuon C, Suarez-Domenech V, Bergmann A, Müller B. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection. Horm Metab Res. 2003;35(5):290–5.

    Article  PubMed  CAS  Google Scholar 

  23. Domenech VS, Nylen ES, White JC, Snider RH, Becker KL, Landmann R, Müller B. Calcitonin gene-related peptide expression in sepsis: postulation of microbial infection-specific response elements within the calcitonin I gene promoter. J Investig Med. 2001;49(6):514–21.

    Article  PubMed  CAS  Google Scholar 

  24. Müller B, White JC, Nylén ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-1 gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001;86(1):396–404.

    Article  PubMed  Google Scholar 

  25. Giunti M, Peli A, Battilani M, Zacchini S, Militerno G, Otto CM. Evaluation of CALC-I gene (CALCA) expression in tissues of dogs with signs of the systemic inflammatory response syndrome. J Vet Emerg Crit Care (San Antonio). 2010;20(5):523–7.

    Article  Google Scholar 

  26. Meisner M, Müller V, Khakpour Z, Toegel E, Redl H. Induction of procalcitonin and proinflammatory cytokines in an anhepatic baboon endotoxin shock model. Shock. 2003;19(2):187–90.

    Article  PubMed  CAS  Google Scholar 

  27. Silomon M, Bach F, Ecker D, Graeter T, Grundmann U, Larsen R. Procalcitonin after extracorporeal circulation. Synthesis in the hepatosplanchnic region. Anaesthesist. 1999;48(6):395–8.

    Article  PubMed  CAS  Google Scholar 

  28. Kretzschmar M, Krüger A, Schirrmeister W. Procalcitonin following elective partial liver resection—origin from the liver? Acta Anaesthesiol Scand. 2001;45(9):1162–7.

    Article  PubMed  CAS  Google Scholar 

  29. Oberhoffer M, Stonans I, Russwurm S, Stonane E, Vogelsang H, Junker U, et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med. 1999;134(1):49–55.

    Article  PubMed  CAS  Google Scholar 

  30. Herget-Rosenthal S, Klein T, Marggraf G, Hirsch T, Jakob HG, Philipp T, Kribben A. Modulation and source of procalcitonin in reduced renal function and renal replacement therapy. Scand J Immunol. 2005;61(2):180–6.

    Article  PubMed  CAS  Google Scholar 

  31. Kuzi S, Aroch I, Peleg K, Karnieli O, Klement E, Dank G. Canine procalcitonin messenger RNA expression. J Vet Diagn Invest. 2008;20(5):629–33.

    Article  PubMed  Google Scholar 

  32. Oberhoffer M, Vogelsang H, Jäger L, Reinhart K. Katacalcin and calcitonin immunoreactivity in different types of leukocytes indicate intracellular procalcitonin content. J Crit Care. 1999;14(1):29–33.

    Article  PubMed  CAS  Google Scholar 

  33. Balog A, Ocsovszki I, Mándi Y. Flow cytometric analysis of procalcitonin expression in human monocytes and granulocytes. Immunol Lett. 2002;84(3):199–203.

    Article  PubMed  CAS  Google Scholar 

  34. Monneret G, Laroche B, Bienvenu J. Procalcitonin is not produced by circulating blood cells. Infection. 1999;27(1):34–5.

    Article  PubMed  CAS  Google Scholar 

  35. Linscheid P, Seboek D, Nylen ES, Langer I, Schlatter M, Becker KL, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology. 2003;144(12):5578–84.

    Article  PubMed  CAS  Google Scholar 

  36. Linscheid P, Seboek D, Schaer DJ, Zulewski H, Keller U, Müller B. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med. 2004;32(8):1715–21.

    Article  PubMed  CAS  Google Scholar 

  37. Koivula I, Hämäläinen S, Jantunen E, Pulkki K, Kuittinen T, Nousiainen T, et al. Elevated procalcitonin predicts Gram-negative sepsis in haematological patients with febrile neutropenia. Scand J Infect Dis. 2011;43(6–7):471–8.

    Article  PubMed  CAS  Google Scholar 

  38. Hatzistilianou M, Rekliti A, Athanassiadou F, Catriu D. Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia. Inflamm Res. 2010;59(5):339–47.

    Article  PubMed  CAS  Google Scholar 

  39. Miedema KG, de Bont ES, Elferink RF, van Vliet MJ, Nijhuis CS, Kamps WA, et al. The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer. 2010. [Epub ahead of print].

  40. Hatzistilianou M, Rekleity A, Athanassiadou F, DeLutiis MA, Conti P, Catriu D. Serial procalcitonin responses in infection of children with secondary immunodeficiency. Clin Invest Med. 2007;30(2):E75–85.

    PubMed  CAS  Google Scholar 

  41. Axer H, Wohlfarth M, Meisner M, Finn S, Ragoschke-Schumm A, Mentzel HJ, et al. Procalcitonin as a marker for severe sepsis in an immunosuppressed patient. Anasthesiol Intensivmed Notfallmed Schmerzther. 2005;40(2):97–102.

    Article  PubMed  CAS  Google Scholar 

  42. Al-Nawas B, Shah PM. Procalcitonin in patients with and without immunosuppression and sepsis. Infection. 1996;24(6):434–6.

    Article  PubMed  CAS  Google Scholar 

  43. Picariello C, Lazzeri C, Valente S, Chiostri M, Attanà P, Gensini GF. Kinetics of procalcitonin in cardiogenic shock and in septic shock. Preliminary data. Acute Card Care. 2010;12(3):96–101.

    Article  PubMed  Google Scholar 

  44. Clodi M, Vila G, Geyeregger R, Riedl M, Stulnig TM, Struck J, Luger TA, et al. Oxytocin alleviates the neuroendocrine and cytokine response to bacterial endotoxin in healthy men. Am J Physiol Endocrinol Metab. 2008;295(3):E686–91.

    Article  PubMed  CAS  Google Scholar 

  45. Preas HL 2nd, Nylen ES, Snider RH, Becker KL, White JC, Agosti JM, et al. Effects of anti-inflammatory agents on serum levels of calcitonin precursors during human experimental endotoxemia. J Infect Dis. 2001;184(3):373–6.

    Article  PubMed  CAS  Google Scholar 

  46. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994;79(6):1605–8.

    Article  PubMed  CAS  Google Scholar 

  47. Charles PE, Ladoire S, Aho S, Quenot JP, Doise JM, Prin S, et al. Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either Gram negative or Gram positive bacteria. BMC Infect Dis. 2008;26(8):38.

    Article  Google Scholar 

  48. Kim KE, Han JY. Evaluation of the clinical performance of an automated procalcitonin assay for the quantitative detection of bloodstream infection. Korean J Lab Med. 2010;30(2):153–9.

    Article  PubMed  CAS  Google Scholar 

  49. von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C, et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis. 2004;23(7):539–44.

    Article  Google Scholar 

  50. Nijsten MW, Olinga P, The TH, de Vries EG, Koops HS, Groothuis GM, et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med. 2000;28(2):458–61.

    Article  PubMed  CAS  Google Scholar 

  51. Kettelhack C, Hohenberger P, Schulze G, Kilpert B, Schlag PM. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan. Crit Care Med. 2000;28(4):1040–6.

    Article  PubMed  CAS  Google Scholar 

  52. Whang KT, Vath SD, Becker KL, Snider RH, Nylen ES, Muller B, et al. Procalcitonin and proinflammatory cytokine interactions in sepsis. Shock. 2000;14(1):73–8.

    Article  PubMed  CAS  Google Scholar 

  53. Papassotiriou I, Alexiou VG, Tsironi M, Skenderi K, Spanos A, Falagas ME. Severe aseptic inflammation caused by long distance running (246 km) does not increase procalcitonin. Eur J Clin Invest. 2008;38(4):276–9.

    Article  PubMed  CAS  Google Scholar 

  54. Chakrabartty S, Apong S. Procalcitonin estimation in Kawasaki disease. Indian Pediatr. 2009;46(7):648.

    PubMed  Google Scholar 

  55. Barati M, Alinejad F, Bahar MA, Tabrisi MS, Shamshiri AR, Bodouhi NO, Karimi H. Comparison of WBC, ESR, CRP and PCT serum levels in septic and non-septic burn cases. Burns. 2008;34(6):770–4.

    Article  PubMed  Google Scholar 

  56. Latour-Pérez J, Alcalá-López A, García-García MA, Sánchez-Hernández JF, Abad-Terrado C, Viedma-Contreras JA, et al. Diagnostic accuracy of sTREM-1 to identify infection in critically ill patients with systemic inflammatory response syndrome. Clin Biochem. 2010;43(9):720–4.

    Article  PubMed  Google Scholar 

  57. Dahaba AA, Hagara B, Fall A, Rehak PH, List WF, Metzler H. Procalcitonin for early prediction of survival outcome in postoperative critically ill patients with severe sepsis. Br J Anaesth. 2006;97(4):503–8.

    Article  PubMed  CAS  Google Scholar 

  58. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001;164(3):396–402.

    PubMed  CAS  Google Scholar 

  59. Steinwald PM, Whang KT, Becker KL, Snider RH, Nylen ES, White JC. Elevated calcitonin precursor levels are related to mortality in an animal model of sepsis. Crit Care. 1999;3(1):11–6.

    Article  PubMed  Google Scholar 

  60. Nylen ES, Whang KT, Snider RH Jr, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med. 1998;26(6):1001–6.

    Article  PubMed  CAS  Google Scholar 

  61. Wagner KE, Martinez JM, Vath SD, Snider RH, Nylén ES, Becker KL, et al. Early immunoneutralization of calcitonin precursors attenuates the adverse physiologic response to sepsis in pigs. Crit Care Med. 2002;30(10):2313–21.

    Article  PubMed  CAS  Google Scholar 

  62. Tavares E, Miñano FJ. Immunoneutralization of the aminoprocalcitonin peptide of procalcitonin protects rats from lethal endotoxaemia: neuroendocrine and systemic studies. Clin Sci (Lond). 2010;119(12):519–34.

    Article  CAS  Google Scholar 

  63. Martinez JM, Wagner KE, Snider RH, Nylen ES, Muller B, Sarani B. Late immunoneutralization of procalcitonin arrests the progression of lethal porcine sepsis. Surg Infect (Larchmt). 2001;2(3):193–202. discussion 202–203.

    Article  CAS  Google Scholar 

  64. Liappis AP, Gibbs KW, Nylen ES, Yoon B, Snider RH, Gao B, et al. Exogenous procalcitonin evokes a pro-inflammatory cytokine response. Inflamm Res. 2011;60(2):203–7.

    Article  PubMed  CAS  Google Scholar 

  65. Wei JX, Verity A, Garle M, Mahajan R, Wilson V. Examination of the effect of procalcitonin on human leucocytes and the porcine isolated coronary artery. Br J Anaesth. 2008;100(5):612–21.

    Article  PubMed  CAS  Google Scholar 

  66. Wiedermann FJ, Kaneider N, Egger P, Tiefenthaler W, Wiedermann CJ, Lindner KH, et al. Migration of human monocytes in response to procalcitonin. Crit Care Med. 2002;30(5):1112–7.

    Article  PubMed  CAS  Google Scholar 

  67. Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M. Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol. 2008;39(2):127–32.

    Article  PubMed  CAS  Google Scholar 

  68. Pincíková T, Bucová M, Slobodníková L. Influence of recombinant human procalcitonin on phagocytic and candidacidal ability of polymorphonuclear leukocytes and on killing mechanisms of serum and blood against bacteria Staphylococcus aureus and Escherichia coli. Vnitr Lek. 2005;51(12):1365–70.

    PubMed  Google Scholar 

  69. Monneret G, Pachot A, Laroche B, Picollet J, Bienvenu J. Procalcitonin and calcitonin gene-related peptide decrease LPS-induced tnf production by human circulating blood cells. Cytokine. 2000;12(6):762–4.

    Article  PubMed  CAS  Google Scholar 

  70. Bucova M, Zahorec R, Buc M. Immunomodulatory effect of recombinant human procalcitonin on mitogenic activity of lymphocytes. Cent Eur J Immunol. 2006;31:87–93.

    CAS  Google Scholar 

  71. Hoffmann G, Schobersberger W. Anti-inflammatory procalcitonin (PTC) in a human whole blood model septic shock. Cytokine. 2000;12(6):762–4.

    Article  Google Scholar 

  72. Hoffmann G, Totzke G, Seibel M, Smolny M, Wiedermann FJ, Schobersberger W. In vitro modulation of inducible nitric oxide synthase gene expression and nitric oxide synthesis by procalcitonin. Crit Care Med. 2001;29(1):112–6.

    Article  PubMed  CAS  Google Scholar 

  73. Hoffmann G, Czechowski M, Schloesser M, Schobersberger W. Procalcitonin amplifies inducible nitric oxide synthase gene expression and nitric oxide production in vascular smooth muscle cells. Crit Care Med. 2002;30(9):2091–5.

    Article  PubMed  CAS  Google Scholar 

  74. Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, Gans RO, et al. Plasma procalcitonin and risk of type 2 diabetes in the general population. Diabetologia. 2011. [Epub ahead of print].

  75. Jereb M, Lunaček NK, Kotar T, Saksida A, Petrovec M, Avšič-Županc T. Procalcitonin in hantavirus infections. Scand J Clin Lab Invest. 2011;71(4):287–91.

    Article  PubMed  CAS  Google Scholar 

  76. Christ-Crain M, Müller B. Procalcitonin and pneumonia: is it a useful marker? Curr Infect Dis Rep. 2007;9(3):233–40.

    Article  PubMed  Google Scholar 

  77. Becker KL, Bivins LE, Radfar RH, Snider RH, Moore CF, Silva OL. Study of calcitonin heterogeneity using a radioreceptor assay. Horm Metab Res. 1978;10(5):457–8.

    Article  PubMed  CAS  Google Scholar 

  78. Jullienne A, Raulais D, Calmettes C, Moukhtar MS, Milhaud G. Heterogeneity of immunoreactive calcitonin in normal human thyroid. Horm Metab Res. 1978;10(5):456–7.

    Article  PubMed  CAS  Google Scholar 

  79. Sexton PM, Christopoulos G, Christopoulos A, Nylen ES, Snider RH Jr, Becker KL. Procalcitonin has bioactivity at calcitonin receptor family complexes: potential mediator implications in sepsis. Crit Care Med. 2008;36(5):1637–40.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Pulmonary Medicine, Naval Medical Center San Diego, San Diego, CA, 92134, USA

    G. N. Matwiyoff, J. D. Prahl, R. J. Miller, J. J. Carmichael, G. Seda & M. Daheshia

  2. Department of Critical Care, Scripps Memorial Hospital, 354 Santa Fe Drive, Encinitas, CA, 92024, USA

    D. E. Amundson

Authors
  1. G. N. Matwiyoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. D. Prahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. J. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. J. Carmichael
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. E. Amundson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Seda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Daheshia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Daheshia.

Additional information

Responsible Editor: Artur Bauhofer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Matwiyoff, G.N., Prahl, J.D., Miller, R.J. et al. Immune regulation of procalcitonin: a biomarker and mediator of infection. Inflamm. Res. 61, 401–409 (2012). https://doi.org/10.1007/s00011-012-0439-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00011-012-0439-5

Keywords

Search

Navigation